These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 4284680)

  • 1. Adsorption of attenuated and neurovirulent poliovirus strains to central nervous system tissues of primates.
    Harter DH; Choppin PW
    J Immunol; 1965 Oct; 95(4):730-6. PubMed ID: 4284680
    [No Abstract]   [Full Text] [Related]  

  • 2. Adsorption of attenuated and neurovirulent strains of poliovirus to central nervous system tissues.
    Harter DH; Choppin PW
    Trans Am Neurol Assoc; 1965; 90():252-3. PubMed ID: 4285568
    [No Abstract]   [Full Text] [Related]  

  • 3. Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis.
    Racaniello VR; Ren R; Bouchard M
    Dev Biol Stand; 1993; 78():109-16. PubMed ID: 8388820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21.
    Nagata N; Iwasaki T; Ami Y; Sato Y; Hatano I; Harashima A; Suzaki Y; Yoshii T; Hashikawa T; Sata T; Horiuchi Y; Koike S; Kurata T; Nomoto A
    Virology; 2004 Mar; 321(1):87-100. PubMed ID: 15033568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice.
    Levenbook I; Nomura T
    Lab Anim Sci; 1997 Apr; 47(2):118-20. PubMed ID: 9150487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on the neurovirulence of the attenuated poliovirus type 3 (USOL-D) in monkey experiments].
    Unterharnscheidt F; Simon J; Bonin O; Günther O; Schmidt K; Schmidt I; Heber L; von Mettenheim A
    Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M; 1966; 62():1-19. PubMed ID: 4287917
    [No Abstract]   [Full Text] [Related]  

  • 7. Poliovirus-sensitive transgenic mice as a new animal model.
    Koike S; Horie H; Sato Y; Ise I; Taya C; Nomura T; Yoshioka I; Yonekawa H; Nomoto A
    Dev Biol Stand; 1993; 78():101-7. PubMed ID: 8388819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice.
    Abe S; Ota Y; Koike S; Kurata T; Horie H; Nomura T; Hashizume S; Nomoto A
    Virology; 1995 Feb; 206(2):1075-83. PubMed ID: 7856082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian somatic cell hybrids and their susceptibility to viral infection.
    Green H; Wang R; Basilico C; Pollack R; Kusano T; Salas J
    Fed Proc; 1971; 30(3):930-4. PubMed ID: 4324981
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates.
    Macadam AJ; Pollard SR; Ferguson G; Skuce R; Wood D; Almond JW; Minor PD
    Virology; 1993 Jan; 192(1):18-26. PubMed ID: 8390752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on new attenuated strains of type III live poliomyelitis vaccine. I. Development of a new type III attenuated poliovirus.
    Chin Med J (Engl); 1980 Sep; 93(9):583-90. PubMed ID: 6253236
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor.
    Yang WX; Terasaki T; Shiroki K; Ohka S; Aoki J; Tanabe S; Nomura T; Terada E; Sugiyama Y; Nomoto A
    Virology; 1997 Mar; 229(2):421-8. PubMed ID: 9126254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on safety tests of inactivated poliomyelitis vaccines. V. Pathomorphological changes in the CNS of rhesus monkeys (Macaca rhesus) and long-tailed monkeys (Cercopithecus aethiops) following intracerebral and intralumbar inoculation with inactivated poliovirus types I, II, and 3].
    Unterharnscheidt F; Günther O; Hövel H; Burde K; Heber L
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):150-66. PubMed ID: 4296871
    [No Abstract]   [Full Text] [Related]  

  • 14. Poliovirus neurovirulence and attenuation, a conceptual framework.
    John TJ
    Dev Biol Stand; 1993; 78():117-9. PubMed ID: 8388822
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential use of poliovirus as a vector.
    Girard M; Martin A; van der Werf S
    Biologicals; 1993 Dec; 21(4):371-7. PubMed ID: 8024753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on safety tests of inactivated poliomyelitis vaccines. IV. Comparative safety tests in rhesus monkeys and long-tailed monkeys (Cercopithecus aethiops)].
    Günther O; Hövel H; von Mettenheim A; Burde K; Heber L; Unterharnscheidt F
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):137-50. PubMed ID: 4296870
    [No Abstract]   [Full Text] [Related]  

  • 17. Action of cation transfer ATPase inhibitors on efficiency of infection with poliovirus.
    Koch A; György E
    Acta Microbiol Acad Sci Hung; 1970; 17(2):127-31. PubMed ID: 4321441
    [No Abstract]   [Full Text] [Related]  

  • 18. [Neurotropism of poliovirus].
    Koike S
    Tanpakushitsu Kakusan Koso; 2007 Aug; 52(10 Suppl):1231-6. PubMed ID: 17824245
    [No Abstract]   [Full Text] [Related]  

  • 19. The molecular basis of poliovirus neurovirulence.
    Ohka S; Nomoto A
    Dev Biol (Basel); 2001; 105():51-8. PubMed ID: 11763337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulence.
    Chumakov K; Norwood L; Parker M; Dragunsky E; Taffs R; Ran Y; Ridge J; Levenbook I
    Dev Biol Stand; 1993; 78():79-89; discussion 88-9. PubMed ID: 8388834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.